Ratings
0
Nobody has rated this yet. Be the first!
Works
4
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers